T Schroeder
Overview
Explore the profile of T Schroeder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
2029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richardson T, Kobbe G, Fenk R, Schroeder T, Crysandt M, Neuerburg C, et al.
Eur J Haematol
. 2024 Nov;
114(3):423-428.
PMID: 39535309
A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients relapse. Allogeneic hematopoietic cell transplantation (allo-SCT) is a...
2.
Sadowska-Klasa A, Zaucha J, Labopin M, Bourhis J, Blaise D, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):387-394.
PMID: 38195982
Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation...
3.
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard J, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):232-238.
PMID: 38007531
Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT...
4.
Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):224-231.
PMID: 37993503
The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to be defined. This is particularly the case for patients with excess...
5.
Wehling A, Loeffler D, Zhang Y, Kull T, Donato C, Szczerba B, et al.
Blood
. 2022 Jul;
140(13):1482-1495.
PMID: 35820055
Molecular programs initiating cell fate divergence (CFD) are difficult to identify. Current approaches usually compare cells long after CFD initiation, therefore missing molecular changes at its start. Ideally, single cells...
6.
Favetti M, Schroeder T, Montagner A, Moraes R, Pereira-Cenci T, Cenci M
Oper Dent
. 2022 May;
47(3):268-278.
PMID: 35584331
This study evaluated the retention of composite resin restorations in noncarious cervical lesions (NCCLs) performed with or without pretreatment with 10% NaOCl solution (deproteinization). A randomized, controlled, split-mouth, double-blinded trial...
7.
Droeser R, Kaneva P, Cheng V, Lam L, Benjamin E, Matsushima K, et al.
Can J Surg
. 2022 Apr;
61(4 Suppl 1):S94-S174.
PMID: 35488393
No abstract available.
8.
Lees J, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, et al.
Phys Rev Lett
. 2022 Apr;
128(13):131802.
PMID: 35426701
Axionlike particles (ALPs) are predicted in many extensions of the standard model, and their masses can naturally be well below the electroweak scale. In the presence of couplings to electroweak...
9.
Lees J, Poireau V, Tisserand V, Grauges E, Palano A, Eigen G, et al.
Phys Rev Lett
. 2022 Mar;
128(9):091804.
PMID: 35302790
We report on the first search for electron-muon lepton flavor violation (LFV) in the decay of a b quark and b antiquark bound state. We look for the LFV decay...
10.
Boquoi A, Banahan S, Mohring A, Savickaite I, Strapatsas J, Hildebrandt B, et al.
Ann Hematol
. 2022 Mar;
101(5):1031-1038.
PMID: 35262868
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after...